Results 91 to 100 of about 34,512 (245)

An Application of a Large‐Scale, Data‐Driven Approach to Prioritize Compound‐Targeted Conditions in the Nutraceutical Space: Case Study of QuercefitTM (Quercetin Phytosome) Toward Unbalanced Lipid Conditions in Metabolically Challenged Adults

Molecular Nutrition &Food Research, EarlyView.
Quercetin, a bioactive flavonoid abundant in fruits and vegetables, exhibits antioxidant and anti‐inflammatory effects with potential benefits in metabolic health. Using a high‐throughput in‐silico repurposing pipeline previously validated in pharmaceutical studies, 33 quercetin gene‐expression signatures were systematically compared against more than ...
Loukia Lili, Sheena Smith, Laura Kunces, Riva Antonella, Pietro Allegrini, Stefano Togni, Serena Tongiani, Nate Rickard, Benjamin Readhead, Stephen Phipps, Bodi Zhang   +10 more
wiley   +1 more source

2-hydroxyglutarate production, but not dominant negative function, is conferred by glioma-derived NADP-dependent isocitrate dehydrogenase mutations. [PDF]

PLoS ONE, 2011
Gliomas frequently contain mutations in the cytoplasmic NADP(+)-dependent isocitrate dehydrogenase (IDH1) or the mitochondrial NADP(+)-dependent isocitrate dehydrogenase (IDH2). Several different amino acid substitutions recur at either IDH1 R132 or IDH2
Genglin Jin, Zachary J Reitman, Ivan Spasojevic, Ines Batinic-Haberle, Jian Yang, Oleg Schmidt-Kittler, Darell D Bigner, Hai Yan   +7 more
doaj   +1 more source

Investigating the mechanisms of indocyanine green tumour uptake in sarcoma cell lines and ex vivo human tissue

The Journal of Pathology, EarlyView.
Abstract Indocyanine green (ICG) is a well‐established near‐infrared dye which has been used clinically for several decades. Recently, it has been utilised for fluorescence‐guided surgery in a range of solid cancer types, including sarcoma, with the aim of reducing the positive margin rate.
Corey David Chan, Marcus J Brookes, Toni A Pringle, Rahul Pal, Riya Tanwani, Alastair D Burt, James C Knight, Anand TN Kumar, Kenneth S Rankin   +8 more
wiley   +1 more source

IDH1: function follows form [PDF]

Science-Business eXchange, 2009
Researchers at Agios Pharmaceuticals have shown that a common cancer-associated mutation causes the enzyme IDH1 to acquire a new catalytic activity while stripping it of its native one. The biotech is exploring the therapeutic potential of its discovery in gliomas and secondary glioblastomas.
openaire   +2 more sources

Predicting medical prognosis in patients with glioblastoma during inpatient rehabilitation using bed mobility function

PM&R, EarlyView.
Abstract Background Determining appropriate suitability and goals for inpatient rehabilitation of patients with glioblastoma, isocitrate dehydrogenase‐wildtype (GBM) requires real‐time prognostic information. Functional measures, such as bed mobility, are standardized scores that can be assessed by members of the care team at the bedside and may aid ...
Tomasz Gruchala, Christopher W. Lewis, Kathryn Abplanalp, Prakash Jayabalan, Theresa L. Walunas, Jodi L. Johnson, Derek A. Wainwright, Rimas V. Lukas, Gayle Spill, Ishan Roy   +9 more
wiley   +1 more source

Bridging the Gap: How Organ‐on‐a‐Chip Technology Facilitates the Battle against Glioma

Small Science, EarlyView.
This review critically evaluates current state‐of‐the‐art in vitro glioma models especially glioma‐on‐a‐chip models based on readout capability, performance, and physiological relevance. It summarizes the key parameters and proposes a practical framework to guide researchers in selecting the most suitable preclinical models for glioma studies.
Su Liu, Zhenyu Gong, Dairan Zhou, Vanesa Ayala‐Nunez, Tao Xu, Peter Wick   +5 more
wiley   +1 more source

Molecular and cellular mechanisms underlying gyrate atrophy: Why is the retina primarily affected?

Acta Ophthalmologica, EarlyView.
Abstract Gyrate atrophy of the choroid and retina (GACR; OMIM #258870) is a rare early‐onset autosomal recessive disorder, caused by bi‐allelic pathogenic variants in the gene coding for ornithine aminotransferase (OAT) resulting in hyperornithinaemia.
Mark J. N. Buijs, Berith M. Balfoort, Marion M. Brands, Anneloor L. M. A. ten Asbroek, Camiel J. F. Boon, Roselie M. H. Diederen, Corrie Timmer, Margreet A. E. M. Wagenmakers, Hans R. Waterham, Ronald J. A. Wanders, Riekelt H. Houtkooper, Clara D. van Karnebeek, Arthur A. Bergen   +12 more
wiley   +1 more source

Comparability of external and internal control patients for the prospective randomized HOVON‐103 trial in older AML patients

British Journal of Haematology, EarlyView.
Summary Real‐world data (RWD) previously contributed to post‐marketing regulatory decision‐making, but are currently also considered as external controls to single‐arm trials. The use of RWD control data may be compromised by methodological issues, urging validation of RWD control cohorts.
Sjoerd J. F. Hermans, Jurjen Versluis, Erik D. van Werkhoven, Yvette van Norden, Jeroen J. W. M. Janssen, Gerwin A. Huls, Thomas Pabst, Dimitri A. Breems, Elizabeth Berkx, Avinash G. Dinmohamed, Peter C. Huijgens, Eric Sträng, Jesús María Hernández Rivas, Marta Sobas, Rosa Ayala Diaz, Joaquin Martinez Lopez, Klaus H. Metzeler, Torsten Haferlach, Christian Thiede, Carin A. Uyl‐de Groot, Lars Bullinger, Bob Löwenberg, Gert J. Ossenkoppele, Francesco Pignatti, Jan J. Cornelissen   +24 more
wiley   +1 more source

Monitoring of measurable residual disease by next‐generation sequencing in patients with acute myeloid leukaemia

British Journal of Haematology, EarlyView.
Summary Measurable residual disease (MRD) is a strong prognostic factor in acute myeloid leukaemia (AML). Next‐generation sequencing (NGS) offers promise but must distinguish true signal from background. We assessed MRD in 98 adult AML patients in first complete remission after intensive chemotherapy using a duplex unique molecular identifier (UMI ...
Augustin Boudry, Laure Goursaud, Delphine Lebon, Florent Dumezy, Véronique Harrivel, Alexandre Boue‐Raguet, Romane Joudinaud, Alice Marceau‐Renaut, Sandrine Geffroy, Carine Hauspie, Jan Brijs, Laurène Fenwarth, Céline Berthon, Jean‐Pierre Marolleau, Martin Figeac, Claude Preudhomme, Nicolas Duployez   +16 more
wiley   +1 more source

Integration of omics data in the diagnosis and therapy of glioblastoma

Brain Pathology, EarlyView.
Integration of omics data in the diagnosis and therapy of glioblastoma. Abstract Since the 2016 update of the WHO Classification of Tumors of the Central Nervous System, omics data have been officially integrated into the diagnostic process for glioblastoma, the most prevalent and aggressive primary malignant brain tumor in adults.
Constantin Möller, Melanie Schoof, Keith L. Ligon, Ulrich Schüller   +3 more
wiley   +1 more source